Bausch + Lomb Announces More Than 50 Scientific Presentations at the 2025 American Society of Cataract and Refractive Surgery Annual Meeting

VAUGHAN, Ontario, April 25, 2025 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced 51 scientific presentations at the American Society of Cataract and Refractive Surgery annual meeting, taking place in Los Angeles April 25–28, 2025.

Scientific posters will highlight the results of studies evaluating the TENEO™ Excimer Laser Platform and enVista Envy™, enVista Aspire™ and IC-8® Apthera™ intraocular lenses (IOLs). Additional presentations will feature clinical insights evaluating MIEBO® (perfluorohexyloctane ophthalmic solution), XIIDRA® (lifitegrast ophthalmic solution) 5% and Blink™ NutriTears® nutritional supplement for dry eyes.

The company will also sponsor educational events focused on these and other Bausch + Lomb products.

See below for the complete list of Bausch + Lomb events and scientific presentations.

Friday April 24, 2025
Lights Camera Cataracts: A New Look at Dry Eye and IOL Technology

  • 6:45 p.m. PT; The Clive Davis Theater at LA Live
  • Speakers: Darrell White, MD, Sheri Rowen, MD, Paul Singh, MD, and Julie Bowen

Saturday April 26, 2025
enVista Envy: Flourish at Every Step

  • 3:00 p.m. PT; Los Angeles Convention Center, ASCRS Tap Room, ASCRS Exhibit Hall
  • Speakers: Michael Patterson, MD, and Lisa Feulner, MD

The Expedited Path to Dry Eye Relief: New Data and Clinical Implications for Addressing Signs and Symptoms

  • 5:30 p.m. PT; JW Marriot Los Angeles, Atrium III
  • Speakers: Eric Donnenfeld, MD, and Preeya Gupta, MD

Current Thinking in Dry Eye Disease: Contemporary Perspectives on a Complex Condition

  • 7:15 p.m. PT; Mastro’s Ocean Club
  • Speakers: Jennifer Loh, MD, and Francis Mah, MD

Poster Presentations

  • “Visual Performance, Defocus, and Patient-Reported Outcomes After Bilateral Implantation of a Novel Refractive Full Vision Range IOL.” Castro et al.
  • “Safety and Efficacy of Transepithelial Photoreactive Keratectomy Compared with Standard Photoreactive Keratectomy.” Ang R.
  • “Retrospective Cases Series: Atypical Cases of Enhanced Monofocal Intraocular Lens Implantation in Patients Undergoing Cataract Surgery.” Stephenson D.
  • “Comparison of the Visual Acuity Outcomes of Two Enhanced Monofocal IOLs Designed to Extend the Range of Vision.” Hu E.
  • “Performance and Safety of Minimally Invasive Trabeculostomy and Micro Sclerostomy Procedures in Human Cadaveric Models.” Lau et al.
  • “Performance and Safety of a Trabeculostomy-Creating Minimally Invasive Glaucoma Surgery device: A 12-Month Open-Label Study.” Grover et al.
  • “Performance and Safety of an Ab-Interno Stent-Less Bleb-Forming Procedure in Open-Angle Glaucoma at 3 Years Follow Up.” Voskanyan L.
  • “Retrospective Case Series of Patients Implanted with a Low-Powered Toric Monofocal IOL with an Enhanced Optic.” Stephenson D.
  • “Retrospective Real-World Study: Performance of an Enhanced Monofocal Toric Intraocular Lens in Patients undergoing Cataract Surgery.”  Stephenson et al.
  • “Performance of an Enhanced Monofocal Intraocular Lens in Patients Undergoing Cataract Surgery: Retrospective Real-World Study.” Donnenfeld et al.
  • “Effect of Chord Mu on Near Visual Acuity, Dysphotopsia, and Satisfaction in Eyes Implanted with a Novel Full Range of Vision IOL.” Wiley et al.
  • “Effect of Simulated Astigmatism on the Visual Performance of a Novel Full Range of Vision Compared to a Monofocal Intraocular Lens.” Liang et al.
  • “Safety of Lifitegrast in Patients with Dry Eye Disease: Analysis of a Postmarketing Database.” Chan et al.
  • “Quantitative and Qualitative Assessment of Real-World Lifitegrast Usage in Patients with Dry Eye Disease.” Mah et al.
  • “Early Adoption and Utilization of Perfluorohexyloctane for Dry Eye Disease.” Nijm et al.
  • “Evaluation of the Efficacy and Safety of a Novel Preservative-Free Formulation of Brimonidine Tartrate Ophthalmic Solution.” Parekh et al.
  • “Assessing Healthcare Provider Approaches to Patient Education on Cosmetic/Aesthetic Product Impact on the Ocular Surface.” Parekh et al.
  • “Conjunctival Hyperemia: A Multi-Country Assessment of Healthcare Professionals’ Perspectives on the Treatment Landscape.” Toyos et al.
  • “Evaluation of the Safety of a Selective α2 Adrenergic Receptor Agonist.” Toyos M.
  • “Evaluation of a Novel Nutritional Supplement to Support Eye Health.” Periman et al.
  • “Intervening in the Dry Eye Inflammatory Cycle with a Novel Nutritional Supplement.” Gupta et al.

Paper Presentations

  • “Comparison of the Optics and Visions of Aberrated Corneas Implanted with Small Aperture and Monofocal IOLs.” Barros et al.
  • “Use of a New Cloud-Based Cataract Surgery Planning Platform to Reduce Surgical Errors.” Lobanoff M.
  • “Comparison of Standard Aberration-fee Monofocal Intraocular Lenses and a Novel Intraocular Lens with Higher-order Aspheric Coefficients and Controlled Curvature Change.” Gouvea et al.
  • “The Influence of Pupil Diameter on the Subjective Quality of Vision Outcomes in Patients Implanted with a Novel Full Range of Vision IOL.” Epitropoulos A.
  • “Evaluation of Phacoemulsification Efficiency Using Machine Settings, Power, and Time from a Cloud-Based Database of 1 Million Surgeries.” Shultz et al.
  • “Visual Performance of Negative Versus Neutral Aspheric Monofocal Intraocular Lenses in Light and Dark Conditions: A Randomized Controlled Trial.” Pantanelli et al.
  • “Analysis of Phacoemulsification Parameters and Differences Among US Surgeons Utilizing a Cloud-Based Database of Two Million Surgical Cases.” Singh P.
  • “Safety And Efficacy of a Novel Monofocal Plus Intraocular Lens with Intermediate Optimized Optics: A Real-World Study.” Riaz K.
  • “Prospective Evaluation of the Mesopic Visual Acuity in Cataract Patients Implanted with a Novel Full Range of Vision IOL.” Shultz M.
  • “Effect of Residual Refraction on Dysphotopsia and Near Vision Outcomes in Eyes Implanted with a Novel Full Range of Vision Intraocular Lens.” Harasymowycz et al.
  • “Comparison of Visual and Patient-Reported Outcomes Following Implantation of a Small Aperture and a Trifocal Intraocular Lens.” Feulner et al.
  • “Small-Aperture Intraocular Lens Implantation in Eyes with Previous Refractive Procedures: an Observational, Single-Site Study.” Ang R.
  • “The Prevalence of Hyperosmolar Tear Film in a Pre-Surgical and 30-Day Post Surgical Cataract Patient Population.” Shah et al.
  • “Real-world Evaluation of the Visual Performance of a Novel Full Range of Vision Intraocular Lens.” Muzychuk et al.
  • “Effect of Residual Astigmatism on Patient Satisfaction and Dysphotopsias Following Implantation of a Novel Full Range of Vision IOL.” Muzychuk et al.
  • “Early Postoperative Outcomes of a Novel Monofocal Plus IOL with Intermediate Optimizedoptics in Patients Undergoing Cataract Surgery.” Stonecipher et al.
  • “In-vivo Performance of a Novel Monofocal Intraocular Lens with Higher-order Aspheric Coefficients and Controlled Curvature Change.” Hill et al.
  • “Retrospective Real-World Evidence Study: User Experience with an Enhanced Monofocal Intraocular Lens.” Patel R.
  • “Presbyopic LASIK (laser-in-situ-keratomileusis) Treatment: 1-Year Clinical Outcomes of Regular and Strong Ablation Profiles.” Ang R.
  • “Outcomes of Laser in Situ Keratomileusis Using an Advanced Excimer Laser System Using an Aspheric Ablation Algorithm to Correct High Myopia.” Stonecipher et al.
  • “Myopic LASIK Using an Advanced Excimer Laser and Aspheric Ablation Algorithm in a Subgroup with Corneal Astigmatism of 1.50 D or Higher.” Krueger et al.
  • “The Impact of Hyperosmolarity on Increased Variation of Light Scatter Following Cataract Surgery.” Nijm L.
  • “Prediction Accuracy of Various IOL Power Calculation Formulas in Patients Implanted with an Aberration-Free Monofocal Toric IOL.” Castro et al.
  • “Physician’s Experience and Patient Outcomes with an Ab Interno Stent-Less Bleb-Forming Procedure in Open-Angle Glaucoma.” Singh P.
  • “Initial Clinical Outcomes of LASIK Using an Advanced Excimer Laser with Aspheric Ablation Profile to Correct Myopia and Myopic Astigmatism.” Waring G.
  • “Early Symptom Relief and Satisfaction with Perfluorohexyloctane Ophthalmic Solution in Dry Eye Disease.” Bacharach et al.
  • “Perfluorohexyloctane Ophthalmic Solution in Patients with Dry Eye Disease and Cataract: Post Hoc Analysis of Pooled Data from Pivotal Trials.” McDonald et al.
  • “Early Effects of Perfluorohexyloctane Ophthalmic Solution on Patient-Reported Symptoms of Dry Eye Disease.” White et al.
  • “The Effect of Lifitegrast 5.0% Solution on Clinical Signs and Biomarkers in Dry Eye Disease.” Donnenfeld E.

Video

  • “Video Using a New Heads Up Microscope of Viscodilation and Trabeculotomy Demonstrating Delayed Blanching of the Episcleral Vessels.” Singh P.

###

Indications and Important Safety Information for Technolas Teneo 317 Model 2 System

Indications for Use. The Technolas Teneo 317 Model 2 is indicated for laser-assisted in situ keratomileusis (LASIK) in: (1) Patients for the reduction or elimination of myopic astigmatism up to -10.00 D MRSE, with sphere between -1.00 D and cylinder between 0.00 and -3.00 D; (2) Patients who are 22 years of age or older; (3) Patients must have a stable refraction in the last 12 months, as documented by previous clinical recordings, i.e., the spherical and cylindrical portions of the manifest distance refraction have not progressed at a rate of more than 0.50 D per year prior to the baseline examination in the eye(s) to be treated.

WARNING. Danger of injury due to failure to observe the patient selection criteria! Failure to observe the contraindications and potential adverse effects may result in serious permanent patient injury. The usage of the laser system is limited to a specific field of applications. Observe the contraindications and potential adverse effects listed in the User Manual before selecting a patient and starting any treatment.

Contraindications. Contraindications of the Technolas Teneo 317 Model 2 include patients: (1) with any type of active connective tissue disease or autoimmune disease; (2) with signs of keratoconus, abnormal corneal topography, and degenerations of the structure of the cornea (including but not limited to pellucid marginal degeneration); (3) with significant dry eyes (severe Dry Eye Syndrome). If patients have severely dry eyes, LASIK may increase the dryness. This may or may not go away. Severe eye dryness may delay healing of the flap or interfere with the surface of the eye after surgery. It may result in poor vision after LASIK; (4) for whom the combination of their baseline corneal thickness and the planned operative parameters for the LASIK procedure would result in less than 250µ of residual corneal thickness from corneal endothelium; (5) with uncontrolled diabetes; (6) with uncontrolled glaucoma; (7) with active eye infections or active inflammation: (8) with recent herpes eye infection or problems resulting from past infections; (9) with known sensitivity to medications used for standard LASIK surgery.

Potential Risks and Side Effects: (1) Miscreated flap; (2) Subconjunctival hemorrhage or bleeding; (3) Wrinkles in flap that may require a flap lift; (4) Corneal erosion/abrasion, epithelia defect; (5) Elevated IOP; (6) Debris or foreign body under flap; (7) Epithelial ingrowth under flap; (8) Debilitating visual symptoms, especially at night; (9) Decreased or fluctuating visual acuity; (10) Decreased ability to see in low-light conditions; (11) Light sensitivity; (12) Dry Eye syndrome; (13) Inadequate treatment result; (14) Regression; (15) Corneal damage; (16) Posterior vitreous detachment or retinal detachment, floaters or vascular accidents; (17) Foreign body sensation or pain (initial postoperative days); also, potentially including chronic eye pain that is resistant to therapy referred to as neuropathic pain; (18) Infection/inflammation; (19) CTK (Central Toxic Keratopathy); (20) Medication intolerance; (21) Ptosis; (22) Cataract; (23) Ocular penetration; (24) Potential risk of psychological harm.

This is not all you need to know. Please see the User Manual for a complete list of safety information, including a full list of contraindications, warnings, precautions and risks.

Caution: Federal (U.S.) law restricts this device to sale, by or on the order of a physician.

enVista Envy toric and non-toric IOL Indications and Important Safety Information

Indications
The enVista Envy hydrophobic acrylic IOL is indicated for primary implantation in the capsular bag of the eye in adult patients for visual correction of aphakia with less than or equal to 1.0 D preoperative corneal astigmatism following removal of a cataractous lens to mitigate the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity to an aspheric monofocal IOL.

The enVista Envy toric hydrophobic acrylic IOL is indicated for primary implantation in the capsular bag of the eye in adult patients for visual correction of aphakia and corneal astigmatism following removal of a cataractous lens to mitigate the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity to an aspheric monofocal IOL.

Warnings/Precautions
Physicians should weigh the potential risk/benefit ratio before implanting the enVista Envy lens under any of the circumstances or conditions outlined in the Instructions for Use labeling. Some visual disturbances may be expected due to the superposition of focused and unfocused multiple images. These may include some perceptions of halos or radial lines around point sources of light (starbursts) under nighttime conditions, glare, double vision, haziness and blurred vision. It is expected that, in a small percentage of patients, the observation of such phenomena will be annoying and may be perceived as a hindrance, particularly in low illumination conditions such as nighttime driving. As with other trifocal IOLs, there is a possibility that visual disturbances may be significant enough that the patient will request explant of the IOL. A reduction in contrast sensitivity as compared to a monofocal IOL may be experienced by some patients, therefore, patients implanted with trifocal IOLs should exercise caution when driving at night or in low light or poor visibility conditions. Care should be taken to achieve IOL centration as IOL decentration may result in patients experiencing visual disturbances or suboptimal vision under certain lighting conditions. The surgeon must target emmetropia to achieve optimal visual performance. Patients should be advised that unexpected outcomes could lead to continued spectacle dependence or the need for secondary surgical intervention (e.g., intraocular lens replacement or repositioning). Please provide a copy of the Patient Information Brochure, which can be found at www.bausch.com/IFU. Posterior capsule opacification (PCO) may significantly affect the vision of patients with multifocal IOLs earlier in its progression than patients with monofocal IOLs. This may be due to the reduced contrast sensitivity observed with multifocal IOLs.

Additional Precautions for Toric IOLs: The enVista Envy Toric IOL has not been evaluated in a clinical study. In general, astigmatism that is corrected with a higher cylinder power IOL can result in clinically significant residual astigmatism. The effect of residual astigmatism at distance, intermediate, and near was evaluated in a clinical study of patients who had been implanted with non-toric enVista Envy IOLs and were induced with cylinder power to simulate various levels of residual astigmatism. If a secondary surgical intervention is necessary to reposition the IOL, explantation should be considered as some patients may have recurrent or persistent issues related to rotational instability and misalignment.

CAUTION: Federal law restricts this device to sale by or on the order of a physician.

ATTENTION: See the Directions for Use for a complete listing of indications and important safety information.

Indications and Important Safety Information for IC-8 Apthera IOL

INDICATIONS: The IC-8 Apthera IOL is indicated for unilateral implantation for the visual correction of aphakia and to create monovision in patients of age 22 or older who have been diagnosed with bilateral operable cataract, who have up to 1.5 D of astigmatism in the implanted eye, and who do not have a history of retinal disease and who are not predisposed to experiencing retinal disease in the future. The device is intended for primary implantation in the capsular bag, in the non-dominant eye, after the fellow eye has already undergone successful implantation (uncorrected distance visual acuity 20/32 or better and best-corrected distance visual acuity 20/25 or better) of a monofocal or monofocal toric IOL that is targeted for emmetropia. The refractive target for the IC-8 Apthera IOL should be -0.75 D. The lens mitigates the effects of presbyopia by providing an extended depth of focus. Compared to an aspheric monofocal or monofocal toric IOL, the lens provides improved intermediate and near visual acuity, while maintaining comparable distance visual acuity.

CONTRAINDICATIONS: (1) Patients with dilated pupil size less than 7.0 mm. (2) Patients with a history of retinal disease including but not limited to, high myopia, diabetes, macular disease, sickle cell disease, retinal tear, retinal detachment, retinal vein occlusion, ocular tumor, uveitis, and patients who are predisposed to experiencing retinal disease in the future.

WARNINGS: The lens should not be implanted if appropriate intraocular support of the lens is not possible. Severe subjective visual disturbances (e.g., glare, halo, starburst, hazy vision) may occur after device implantation. There is a possibility that these visual disturbances may be significant enough that a patient may request removal of the lens. Contrast sensitivity in eyes implanted with this lens is significantly reduced when compared to the fellow eye implanted with a monofocal or monofocal toric IOL. Although there was no significant reduction in binocular contrast sensitivity in the IDE clinical study, it is essential that prospective patients be fully informed of this visual effect in the implanted eye before giving their consent for unilateral implantation of the lens. Patients should be informed that they may need to exercise caution when engaging in activities that require good vision in dimly lit environments (such as driving at night or in poor visibility conditions). There is a possibility that visual symptoms due to reduced contrast sensitivity may be significant enough that a patient may request removal of the lens. This lens should not be implanted bilaterally because bilateral implantation is expected to cause significant reduction in contrast sensitivity under all lighting conditions. The use of this lens in patients with corneal astigmatism greater than 1.5 D is not recommended. Diagnostic tests in patients implanted with the lens may take longer and require some additional effort from the patient and the physician to perform. Use of some medical lasers to treat certain eye conditions may present potential risks of damaging the FilterRing component of the lens. Removal of the lens may be necessary prior to retinal or vitreal procedures. Surgeons should perform a careful benefit-risk assessment based on individual patient characteristics, weighing all the risks disclosed in the Directions for Use labeling against the benefit of extended depth of focus. Nd:YAG laser capsulotomy treatments may be more difficult to perform and may be less effective in an IC-8 Apthera IOL implanted eye. Specific training from Bausch & Lomb, Inc. or its authorized representative related to YAG capsulotomy is required before a surgeon is authorized to implant the IC-8 Apthera IOL.

PRECAUTIONS: Prior to surgery, prospective patients should be informed of the possible risks and benefits associated with this lens and a Patient Information Brochure should be provided to the patient. Patients with a predicted postoperative astigmatism between 1.0 D and 1.5 D may not obtain as great an amount of improvement in intermediate vision compared to patients with lower amounts of astigmatism.

CAUTION: Federal law restricts this device to sale by or on the order of a licensed physician.

ATTENTION: Reference the Directions for Use labeling for a complete listing of important safety information.

Important Safety Information for MIEBO

INDICATION
MIEBO (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

  • MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO
  • Instruct patients to instill one drop of MIEBO into each eye four times daily
  • The safety and efficacy in pediatric patients below the age of 18 have not been established
  • The most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)

Click here for full Prescribing Information for MIEBO.

Important Safety Information for XIIDRA

Indication
Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

  • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
  • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
  • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
  • Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
  • Safety and efficacy in pediatric patients below the age of 17 years have not been established.

Click here for full Prescribing Information for XIIDRA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

NUTRITEARS is a trademark of OmniActive Health Technologies Ltd., used under license.

About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.

Media Contact:

Caryn Marshall
[email protected]
(908) 493-1381

© 2025 Bausch + Lomb.
MTB.0254.USA.25

Back to Press Releases